← Leaderboards
Rebecca E Amariglio
Brigham And Women'S Hospital
$4,746,581
Attributed
$4,746,581
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $838.9K · FY2014–24$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,746,581 · 2
By mechanism
R01$4,004,860 · 1
K23$741,721 · 1
Top collaborators
No co-investigators on record.
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Thomas Glenn Travison$4,113,118
- Neil Resnick$10,494,163
- Charles L. Dumoulin$1,261,242
- Patrizia Vannini$5,883,504
- Mark G Baxter$13,760,448
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS DiseasePositron-Emission TomographyPatient Self-ReportParticipantNeuropsychological TestsCohortBiological MarkersEarly DiagnosisHigh RiskMemoryMagnetic Resonance ImagingAmyloidCognitiveAmyloid Beta-ProteinImpaired CognitionAmyloid ImagingCarrier StatusAging BrainDisease ProgressionEpisodic MemoryExecutive FunctionInvestigationPerformance
Grant awards (10)
Characterizing the evolution of Subjective Cognitive Decline in preclinical Alzheimer's disease$747,953
R01 · FY2024 · AG · contact PI
Characterizing the evolution of Subjective Cognitive Decline in preclinical Alzheimer's disease$759,588
R01 · FY2023 · AG · contact PI
Characterizing the evolution of Subjective Cognitive Decline in preclinical Alzheimer's disease$823,375
R01 · FY2022 · AG · contact PI
Characterizing the evolution of Subjective Cognitive Decline in preclinical Alzheimer's disease$838,874
R01 · FY2020 · AG · contact PI
Characterizing the evolution of Subjective Cognitive Decline in preclinical Alzheimer's disease$835,070
R01 · FY2019 · AG · contact PI
Optimizing measures of subjective and objective decline in preclinical AD$168,909
K23 · FY2018 · AG · contact PI
Optimizing measures of subjective and objective decline in preclinical AD$168,592
K23 · FY2017 · AG · contact PI
Optimizing measures of subjective and objective decline in preclinical AD$132,227
K23 · FY2016 · AG · contact PI
Optimizing measures of subjective and objective decline in preclinical AD$135,912
K23 · FY2015 · AG · contact PI
Optimizing measures of subjective and objective decline in preclinical AD$136,081
K23 · FY2014 · AG · contact PI